Search

Your search keyword '"BRENTUXIMAB VEDOTIN"' showing total 1,844 results

Search Constraints

Start Over You searched for: Descriptor "BRENTUXIMAB VEDOTIN" Remove constraint Descriptor: "BRENTUXIMAB VEDOTIN" Database OpenAIRE Remove constraint Database: OpenAIRE
1,844 results on '"BRENTUXIMAB VEDOTIN"'

Search Results

1. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH)

2. Evolving Landscape of Antibody Drug Conjugates in Lymphoma

Catalog

Books, media, physical & digital resources

3. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

4. Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

5. Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management

6. CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma

7. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

8. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

9. Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

10. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study

11. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

12. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

13. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience

14. First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology

15. Cutaneous CD30-positive lymphoproliferations

17. Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

18. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs

19. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

20. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China

21. Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events

22. Treatment of mycosis fungoides with brentuximab vedotin: Assessing <scp>CD30</scp> expression by immunohistochemistry and quantitative real‐time polymerase chain reaction

23. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors

24. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

25. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma

26. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease

27. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma

28. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation

29. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

30. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma

31. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

32. Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

33. Epstein-Barr virus–positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma

34. Long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high‐risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party‐EBMT

35. The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

36. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study

37. Modern possibilities of therapy for primary cutaneous T-cell lymphomas: the first results of the use of brentuximab vedotin in the Russian Federation

38. Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study

39. Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma

40. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

41. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

44. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

45. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma

46. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

47. Folliculotropic mycosis fungoides

48. Treatment of peripheral T-cell lymphomas

49. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

50. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*